MICHAEL BIGHAM - 13 Dec 2021 Form 4 Insider Report for Paratek Pharmaceuticals, Inc.

Role
Exec. Chairman of the Board, Director
Signature
/s/ William M. Haskel, Attorney-in-Fact for Michael Bigham
Issuer symbol
N/A
Transactions as of
13 Dec 2021
Net transactions value
-$136,126
Form type
4
Filing time
15 Dec 2021, 20:02:01 UTC
Previous filing
24 Nov 2021
Next filing
23 Mar 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PRTK Common Stock Sale $22,361 -5,059 -0.55% $4.42 917,223 13 Dec 2021 Direct F1, F2
transaction PRTK Common Stock Sale $37,678 -8,622 -0.94% $4.37 908,601 14 Dec 2021 Direct F1, F3
transaction PRTK Common Stock Sale $76,087 -17,819 -2% $4.27 890,782 15 Dec 2021 Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Sale of shares to cover personal income tax obligations upon vesting of restricted stock unit award, pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $4.31 to $4.52. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 2 to this Form 4
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $4.20 to $4.48. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 3 to this Form 4.
F4 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $4.11 to $4.34. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 to this Form 4.